Abstract:Botulinum neurotoxin serotype E (BoNT/E) is one of the major causes of human botulism, which is a life-threatening disease caused by flaccid paralysis of muscles. After receptor-mediated toxin internalization into motor neurons, the translocation domain (HN) of BoNT/E transforms into a protein channel upon vesicle acidification in endosomes and delivers its protease domain (LC) across membrane to enter the neuronal cytosol. It is believed that the rapid onset of BoNT/E intoxication compared to other BoNT serot… Show more
“…We report here the use of recent crystal structure and mechanistic data for two BoNT/E-neutralizing VHHs, JLE-E5 and JLE-E9 [28], and the use of these data to predict and then validate the mechanisms by which they neutralize intoxication of neurons. To test these VHHs as heterodimeric VNAs we prepared four different constructs, each containing two of the original three BoNT/E-neutralizing VHHs from Table 1 (JLE-E5, JLE-E9 and JLE-G6).…”
Section: Discussionmentioning
confidence: 99%
“…Three BoNT/E-neutralizing VHHs (JLE-E5, JLE-E9 and JLE-G6) were identified among the VHHs selected on coated ciBoNTE (Table 1). In co-crystallization studies, JLE-E5 and JLE-E9 have now been studied for their mechanisms of neutralization and both were shown to neutralize intoxication by inhibiting BoNT/E endosomal membrane association [28]. JLE-G6 binds to the H C E receptor binding domain of BoNT/E, and thus likely neutralizes the toxin by inhibiting its ability to bind its neuronal receptors, SV2 and/or gangliosides [25].…”
Section: Vhh Monomer Neutralization Of Bont/e In Neuronal Culturesmentioning
confidence: 99%
“…We next produced a fourth 'designer' VNA by incorporating new structural information [28] predicted to result in enhanced neutralization properties [25]. Prior studies showed that creating bivalent VNAs that could bind simultaneously to the target is an efficient strategy to increase affinity and potency.…”
Section: Vhh Heterodimer Neutralization Of Bont/e In Micementioning
confidence: 99%
“…Based on the precise binding sites for JLE-E5 and JLE-E9, which bind to closely apposed epitopes on BoNT/E [28], we engineered a VNA called JLE-E9/40/JLE-E5 which was predicted to have the optimal VHH orientation and spacer length to facilitate the ability of both VHH components to bind simultaneously to their BoNT/E epitopes (Figure 4A,B). To test for simultaneous binding, we performed gel filtration studies (Figure 4C) as previously reported [25].…”
Section: Vhh Heterodimer Neutralization Of Bont/e In Micementioning
confidence: 99%
“…VHHs were characterized for the ability to neutralize BoNT/E intoxication of neurons and/or to inhibit LC/E protease cleavage of Synaptosomal-Associated Protein, 25kDa (SNAP-25). To test their in vivo potential as antitoxins, several VHH heterodimeric VNAs were prepared and compared for their BoNT/E antitoxin potencies in mice, including one 'designer' VNA consisting of two closely apposed VHHs linked for simultaneous binding to BoNT/E based on crystal structure data [28].…”
Botulinum neurotoxin (BoNT) serotype E is one of three serotypes that cause the preponderance of human botulism cases and is a Tier 1 Select Agent. BoNT/E is unusual among BoNT serotypes for its rapid onset and short duration of intoxication. Here we report two large panels of unique, unrelated camelid single-domain antibodies (VHHs) that were selected for their ability to bind to BoNT/E holotoxin and/or to the BoNT/E light chain protease domain (LC/E). The 19 VHHs which bind to BoNT/E were characterized for their subunit specificity and 8 VHHs displayed the ability to neutralize BoNT/E intoxication of neurons. Heterodimer antitoxins consisting of two BoNT/E-neutralizing VHHs, including one heterodimer designed using structural information for simultaneous binding, were shown to protect mice against co-administered toxin challenges of up to 500 MIPLD50. The 22 unique VHHs which bind to LC/E were characterized for their binding properties and 9 displayed the ability to inhibit LC/E protease activity. Surprisingly, VHHs selected on plastic-coated LC/E were virtually unable to recognize soluble or captured LC/E while VHHs selected on captured LC/E were poorly able to recognize LC/E coated to a plastic surface. This panel of anti-LC/E VHHs offer insight into BoNT/E function, and some may have value as components of therapeutic antidotes that reverse paralysis following BoNT/E exposures.
“…We report here the use of recent crystal structure and mechanistic data for two BoNT/E-neutralizing VHHs, JLE-E5 and JLE-E9 [28], and the use of these data to predict and then validate the mechanisms by which they neutralize intoxication of neurons. To test these VHHs as heterodimeric VNAs we prepared four different constructs, each containing two of the original three BoNT/E-neutralizing VHHs from Table 1 (JLE-E5, JLE-E9 and JLE-G6).…”
Section: Discussionmentioning
confidence: 99%
“…Three BoNT/E-neutralizing VHHs (JLE-E5, JLE-E9 and JLE-G6) were identified among the VHHs selected on coated ciBoNTE (Table 1). In co-crystallization studies, JLE-E5 and JLE-E9 have now been studied for their mechanisms of neutralization and both were shown to neutralize intoxication by inhibiting BoNT/E endosomal membrane association [28]. JLE-G6 binds to the H C E receptor binding domain of BoNT/E, and thus likely neutralizes the toxin by inhibiting its ability to bind its neuronal receptors, SV2 and/or gangliosides [25].…”
Section: Vhh Monomer Neutralization Of Bont/e In Neuronal Culturesmentioning
confidence: 99%
“…We next produced a fourth 'designer' VNA by incorporating new structural information [28] predicted to result in enhanced neutralization properties [25]. Prior studies showed that creating bivalent VNAs that could bind simultaneously to the target is an efficient strategy to increase affinity and potency.…”
Section: Vhh Heterodimer Neutralization Of Bont/e In Micementioning
confidence: 99%
“…Based on the precise binding sites for JLE-E5 and JLE-E9, which bind to closely apposed epitopes on BoNT/E [28], we engineered a VNA called JLE-E9/40/JLE-E5 which was predicted to have the optimal VHH orientation and spacer length to facilitate the ability of both VHH components to bind simultaneously to their BoNT/E epitopes (Figure 4A,B). To test for simultaneous binding, we performed gel filtration studies (Figure 4C) as previously reported [25].…”
Section: Vhh Heterodimer Neutralization Of Bont/e In Micementioning
confidence: 99%
“…VHHs were characterized for the ability to neutralize BoNT/E intoxication of neurons and/or to inhibit LC/E protease cleavage of Synaptosomal-Associated Protein, 25kDa (SNAP-25). To test their in vivo potential as antitoxins, several VHH heterodimeric VNAs were prepared and compared for their BoNT/E antitoxin potencies in mice, including one 'designer' VNA consisting of two closely apposed VHHs linked for simultaneous binding to BoNT/E based on crystal structure data [28].…”
Botulinum neurotoxin (BoNT) serotype E is one of three serotypes that cause the preponderance of human botulism cases and is a Tier 1 Select Agent. BoNT/E is unusual among BoNT serotypes for its rapid onset and short duration of intoxication. Here we report two large panels of unique, unrelated camelid single-domain antibodies (VHHs) that were selected for their ability to bind to BoNT/E holotoxin and/or to the BoNT/E light chain protease domain (LC/E). The 19 VHHs which bind to BoNT/E were characterized for their subunit specificity and 8 VHHs displayed the ability to neutralize BoNT/E intoxication of neurons. Heterodimer antitoxins consisting of two BoNT/E-neutralizing VHHs, including one heterodimer designed using structural information for simultaneous binding, were shown to protect mice against co-administered toxin challenges of up to 500 MIPLD50. The 22 unique VHHs which bind to LC/E were characterized for their binding properties and 9 displayed the ability to inhibit LC/E protease activity. Surprisingly, VHHs selected on plastic-coated LC/E were virtually unable to recognize soluble or captured LC/E while VHHs selected on captured LC/E were poorly able to recognize LC/E coated to a plastic surface. This panel of anti-LC/E VHHs offer insight into BoNT/E function, and some may have value as components of therapeutic antidotes that reverse paralysis following BoNT/E exposures.
Botulinum neurotoxin E (BoNT/E) is one of the major causes of human botulism and paradoxically also a promising therapeutic agent. Here we determined the co-crystal structures of the receptor-binding domain of BoNT/E (HCE) in complex with its neuronal receptor synaptic vesicle glycoprotein 2A (SV2A) and a nanobody that serves as a ganglioside surrogate. These structures reveal that the protein-protein interactions between HCE and SV2 provide the crucial location and specificity information for HCE to recognize SV2A and SV2B, but not the closely related SV2C. At the same time, HCE exploits a separated sialic acid-binding pocket to mediate recognition of an N-glycan of SV2. Structure-based mutagenesis and functional studies demonstrate that both the protein-protein and protein-glycan associations are essential for SV2A-mediated cell entry of BoNT/E and for its potent neurotoxicity. Our studies establish the structural basis to understand the receptor-specificity of BoNT/E and to engineer BoNT/E variants for new clinical applications.
In this study, we characterize Designed Ankyrin Repeat Proteins (DARPins) as investigative tools to probe botulinum neurotoxin A1 (BoNT/A1) structure and function. We identify DARPin-F5 that completely blocks SNAP25 substrate cleavage by BoNT/A1 in vitro. X-ray crystallography reveals that DARPin-F5 inhibits BoNT/A1 activity by interacting with a substrate-binding region between the α- and β-exosite. This DARPin does not block substrate cleavage of BoNT/A3, indicating that DARPin-F5 is a subtype-specific inhibitor. BoNT/A1 Glu-171 plays a critical role in the interaction with DARPin-F5 and its mutation to Asp, the residue found in BoNT/A3, results in a loss of inhibition of substrate cleavage. In contrast to the in vitro results, DARPin-F5 promotes faster substrate cleavage of BoNT/A1 in primary neurons and muscle tissue by increasing toxin translocation. Our findings could have important implications for the application of BoNT/A1 in therapeutic areas requiring faster onset of toxin action combined with long persistence.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.